Fri, Aug 22, 2014, 3:25 AM EDT - U.S. Markets open in 6 hrs 5 mins

Recent

% | $
Quotes you view appear here for quick access.

Seattle Genetics Inc. Message Board

mghmd 9 posts  |  Last Activity: Aug 11, 2014 5:07 PM Member since: Jan 22, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    This Stinks! Vote NO! File a lawsuit!

    by sjohns544 Aug 10, 2014 11:04 PM
    mghmd mghmd Aug 11, 2014 5:07 PM Flag

    I am in the same situation. I will vote NO unless there is a much larger premium.

  • mghmd by mghmd Jul 24, 2014 8:57 AM Flag

    Dr. Sharman's CLL & NHL Blog
    Idelalisib / Zydelig approved
    Posted: 23 Jul 2014 09:37 AM PDT
    There is a new kid on the block!

    First it was called CAL-101. It is common for a drug company to use letters from the name of the company. In this case, it was originally Calistoga Pharmaceuticals. The 101 part is a little more funny. I understand one of the early investors in the company was driving in Palo Alto California and turned from University Drive onto the 101 highway and decided to call the drug CAL-101. True? False? Not sure.

    Then Gilead bought up the drug from Calistoga. Next step? Change the numbers. CAL-101 became GS-1101. GS = Gilead Science. Not sure where the extra "1" came from. Perhaps it was an effort to differentiate from GA-101 which became obinutuzumab before it became Gazyva.

    Next step is to give the letter / number combo an actual name. In this case it was idelalisib. As difficult as that seems, it actually makes perfect sense.

    Idelalisib (pronounced I-Dela-Lisib)
    I=inhibit
    Dela= delta isoform of PI3K
    Lisib = that is the mandatory suffix of drugs that inhibit PI3K enzymes

    I have heard this drug mispronounced so many ways that it is almost comical -I-del-isilib, I-dela-mab, etc. I think I would have chosen Ideltalisib if I were in control of all things as that would make a lot of sense (inhibit-delta-PI3K).

    Every drug has two names (brand name vs generic name). You would be amazed how much effort goes into coming up with a name for a drug. You would also be amazed how often drug names begin with the letter "Z." Some sort of market research I don't know about I suppose. So idelalisib is now called Zydelig. I think this is a combo of the "z" and the "delta" but not sure I know where the "ig" comes from.

    As if we were not already spoiled by approvals of the latest treatments for CLL including the addition of obinutuzumab and ibrutinib within the last 12 months, now we have yet another new agent that is simultaneously

  • up on a down day on big volume

  • It appears momentum is developing in KPTI based on the realization that multiple ph2 studies in a wide variety of CA have been started. Don't think they have found a type of cancer yet where Selinexor hasn't at least led to stable disease, with objective tumor regression in several other ph1 studies. With such a broad range of oncologic response, this could be a MAJOR advance

    Sentiment: Strong Buy

  • 1.Impressive phase 1 data in advanced prostate cancer and phase 2 for this indication has commenced.
    2. FDA has granted orphan drug status for diffuse large B cell lymphoma based on very promising phase 1 data in this malignancy
    3.Impressive phase 1 data for colorectal cancer as well, with imminent start of phase 2 for this cancer

    And the list goes on. Be careful shorting this stock with excellent science and the potential to be effective for MANY different types of cancer

  • As a hematologist with 40 years experience, I am very impressed with the results of sel/dex in very advanced cases, and with a low side effect profile. Larger studies are obviously needed, but this is a powerful signal for effectiveness of the drug in myeloma.

  • mghmd by mghmd Jun 2, 2014 11:01 AM Flag

    The studies at ASCO are pretty amazing. I am buying heavily. I anticipate several broker upgrades in near future

    Sentiment: Strong Buy

  • As a hematologist with 40 years experience, the results look great and worth far more then 3.5% rise. I just bought more

  • PFE dropped 10% after announcing AZN bid. Nothing bad for PFE during this period, so I can't understand why not regaining the 10%. I bought more this morning.

SGEN
42.99-0.27(-0.62%)Aug 20 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.